*From the Authors*:

We thank Fisk and Wilkinson for their interest in our study showing that higher baseline pulse wave velocity (PWV) was predictive of increased all-cause mortality among patients with chronic obstructive pulmonary disease (COPD) in the SUMMIT (Study to Understand Mortality and Morbidity in COPD) trial ([@bib1]). They raise several important points in their letter. First, the legend of Figure 1 in our article lists the numerous covariables included in the Cox model. Many of the factors, such as diabetes and cardiovascular disease (CVD) or other risk factors, were included in the model among the "cardiovascular entry criteria" (*see* main paper \[[@bib2]\]). Cholesterol concentrations *per se* were not measured. However, blood pressure (in particular) and heart rate are independent predictors of PWV and were not included in the model ([@bib3]). We acknowledge this as a limitation, but we note that there are numerous covariables already in the model with a wide nonsignificant confidence interval. It is unlikely that adjusting for more variables, including blood pressure, would further strengthen the association.

Fisk and Wilkinson correctly note that the study's primary endpoint was all-cause mortality, and as such, we chose to evaluate the association of PWV with this endpoint. In the entire patient population with moderate airflow limitation, we expected that most deaths would be cardiovascular in nature ([@bib4]), and in fact, 43% of all deaths in SUMMIT were adjudicated as cardiovascular; of these deaths, 9% were caused by myocardial infarction, 9% were caused by cerebrovascular accidents, 70% were sudden deaths, 1% were cardiac surgery--related procedural deaths, and 10% were of other cardiovascular causes ([@bib2]). As noted, we did not observe a significant association of PWV with the composite cardiovascular endpoint. Given the fewer number of cardiovascular composite events, our study likely lacked the power to detect this association or statistical significance for any of its individual components. We did not separately analyze the adjudicated cause of death for those in the pulse wave analysis subpopulation, and we recognize this limitation as our inability to identify the specific cause of death related to increased PWV in our analysis. Nevertheless, increased PWV has been shown to be an independent predictor of all-cause mortality in prior meta-analyses ([@bib5]), and we demonstrated in SUMMIT that this association was generally observed in patients with COPD.

Finally, we agree that few novel risk factors are capable of adding incremental risk prognostic information to global risk scores ([@bib6]). We did not make the claim that clinical practice would be changed by evaluating PWV in patients with COPD, and indeed, we clearly stated that "aggressive treatment focusing on improving CVD risk factors is paramount." Our findings support that future trials should evaluate if a portion of the heightened CVD risk observed in patients with COPD is independently mediated by impaired arterial compliance. Nevertheless, we did not observe that treating COPD with inhaler therapy could reduce PWV, and as such, the mainstay of treatment in such patients with concomitant CVD should be to treat traditional CVD risk factors aggressively.
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